The 5 Most Interesting Analyst Questions From Labcorp's Q4 Earnings Call

Labcorp’s Q4 results came in below Wall Street’s revenue expectations, leading to a negative market reaction, while management attributed performance to strength in specialty testing and expanded partnerships with hospitals and regional labs. CEO Adam Schechter highlighted the company’s double-digit growth in esoteric testing and the successful integration of recent acquisitions, including Invitae and assets from various health systems. Schechter also acknowledged that lower organic volume growth was partly due to reduced referrals from a major consumer genetic client and mild weather disruptions, but indicated these were largely isolated events. The quarter was further supported by ongoing cost discipline and advancements in automation and artificial intelligence across core laboratory and consumer services.

Is now the time to buy LH? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Labcorp’s Q4 Earnings Call

• Daniel Christopher Clark (Leerink Partners) asked how price and volume would contribute to guidance. CEO Adam Schechter explained that roughly half of organic growth is expected from each, consistent with prior trends.
• Kevin Caliendo (UBS) probed the soft Q4 organic volume, to which Schechter attributed a onetime client issue and minor weather disruption, both expected to be resolved for 2026.
• Ann Hynes (Mizuho) questioned the biggest risks in 2026 guidance. Schechter cited potential variability in organic volumes and M&A timing, but confidence in the pipeline and industry trends.
• Jack Meehan (Nephron Research) inquired about PAMA’s impact and central lab investments. Schechter described ongoing advocacy for legislative reform and detailed the strategic expansion of central lab facilities to support long-term growth.
• Lisa Gill (JPMorgan) asked about Medicaid headwinds, weather impacts, and margin expansion. CFO Julia Wang confirmed that volume guidance reflects anticipated ACA changes, weather disruptions are factored into forecasts, and margin growth should remain strong.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will closely watch (1) the pace of specialty test adoption and its impact on Labcorp’s product mix, (2) progress on new and existing hospital partnership deals and their revenue contribution, and (3) the effectiveness of operational efficiency programs, including the LaunchPad initiative and Early Development restructuring. Advances in automation, AI integration, and the ramp-up of central laboratory investments will also be important indicators of execution.

Labcorp currently trades at $280.00, in line with $282.63 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.